Potent Covalent Irreversible Inhibitor of KRAS G12C IBI351 in Patients with Advanced Solid Tumors: First-In-Human Phase I Study

IBI351 is an irreversible and covalent inhibitor of KRAS G12C. Despite FDA approval of two KRAS G12C inhibitors, there are still significant unmet clinical needs in Chinese patients and ongoing concerns about the optimal dosage. Herein, we presented the phase Ia/Ib study of IBI351 monotherapy in Chinese patients with advanced solid tumors harboring KRAS G12C mutation.